Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.75 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941079 | 0.88 | SLC6A9 (0.75) | SLC6A9GPR55MAPTLMNASLC6A5 | |
| SCHEMBL4948286 | 0.87 | SLC6A9 (0.79) | SLC6A9GPR55SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL4938264 | 0.86 | SLC6A9 (0.76) | SLC6A9GPR55 | |
| SCHEMBL4940799 | 0.85 | SLC6A9 (0.76) | SLC6A9GPR55SMN1; SMN2MAPK1 | |
| SCHEMBL4941566 | 0.85 | SLC6A9 (0.76) | SLC6A9GPR55SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL4422354 | 0.85 | SLC6A9 (1.00) | SLC6A9GPR55 | |
| SCHEMBL4938017 | 0.84 | SLC6A9 (0.74) | SLC6A9GPR55MEN1KMT2A | |
| SCHEMBL4943078 | 0.84 | SLC6A9 (0.79) | SLC6A9GPR55 | |
| SCHEMBL4941678 | 0.83 | SLC6A9 (0.73) | SLC6A9GPR55MAPTLMNAALDH1A1 | |
| SCHEMBL4941604 | 0.83 | SLC6A9 (0.84) | SLC6A9GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | SLC6A9 9/4885GPR55 485/4885MAPT 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.